MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

12 Aug 2025 Evaluate
The company witnessed a 8.85% growth in the revenue at Rs. 178.92 millions for the quarter ended June 2025 as compared to Rs. 164.37 millions during the year-ago period.Profit for the quarter ended June 2025 grew by 0.88% to Rs. 17.29 millions from Rs. 17.14 millions.Operating profit surged to 26.82 millions from the corresponding previous quarter of 24.23 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 178.92 164.37 8.85 178.92 164.37 8.85 700.99 544.10 28.83
Other Income 0.36 0.86 -58.14 0.36 0.86 -58.14 12.14 5.17 134.82
PBIDT 26.82 24.23 10.69 26.82 24.23 10.69 115.73 87.58 32.14
Interest 2.19 0.16 1268.75 2.19 0.16 1268.75 5.93 2.54 133.46
PBDT 24.63 24.07 2.33 24.63 24.07 2.33 109.80 85.04 29.12
Depreciation 1.64 1.33 23.31 1.64 1.33 23.31 6.21 9.33 -33.44
PBT 22.99 22.74 1.10 22.99 22.74 1.10 103.59 75.71 36.82
TAX 5.70 5.60 1.79 5.70 5.60 1.79 22.58 14.07 60.48
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 4.13 0.48 760.42
PAT 17.29 17.14 0.88 17.29 17.14 0.88 81.01 61.64 31.42
Equity 118.82 116.84 1.69 118.82 116.84 1.69 118.82 116.84 1.69
PBIDTM(%) 14.99 14.74 1.69 14.99 14.74 1.69 16.51 16.10 2.57
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..